Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Net Income: 2019-2024

Historic Net Income for 4D Molecular Therapeutics (FDMT) over the last 6 years, with Dec 2024 value amounting to -$160.8 million.

  • 4D Molecular Therapeutics' Net Income fell 29.68% to -$56.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$209.1 million, marking a year-over-year decrease of 45.83%. This contributed to the annual value of -$160.8 million for FY2024, which is 59.74% down from last year.
  • Latest data reveals that 4D Molecular Therapeutics reported Net Income of -$160.8 million as of FY2024, which was down 59.74% from -$100.7 million recorded in FY2023.
  • 4D Molecular Therapeutics' Net Income's 5-year high stood at -$56.5 million during FY2020, with a 5-year trough of -$160.8 million in FY2024.
  • In the last 3 years, 4D Molecular Therapeutics' Net Income had a median value of -$107.5 million in 2022 and averaged -$123.0 million.
  • In the last 5 years, 4D Molecular Therapeutics' Net Income rose by 6.33% in 2023 and then slumped by 59.74% in 2024.
  • Yearly analysis of 5 years shows 4D Molecular Therapeutics' Net Income stood at -$56.5 million in 2020, then decreased by 25.98% to -$71.2 million in 2021, then slumped by 50.93% to -$107.5 million in 2022, then rose by 6.33% to -$100.7 million in 2023, then crashed by 59.74% to -$160.8 million in 2024.